ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL595
CHEMBL595
Compound Name PIOGLITAZONE
ChEMBL Synonyms U-72107A | Duetact | Actos | Pioglitazone | Pioglitazone HCl
Max Phase 4 (Approved)
Trade Names Actos | Pioglitazone HCl
Molecular Formula C19H20N2O3S

Additional synonyms for CHEMBL595 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
Standard InChI InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4- ...
Download InChI
Standard InChI Key HYAFETHFCAUJAY-UHFFFAOYSA-N

Mechanism of Action

Mechanism of Action ChEMBL Target References
Peroxisome proliferator-activated receptor gamma agonist Peroxisome proliferator-activated receptor gamma DailyMed

Indications for CHEMBL595

MESH Heading MESH ID EFO ID EFO Term Max phase for indication
ALZHEIMER DISEASED000544EFO:0000249ALZHEIMERS DISEASE2
AMYOTROPHIC LATERAL SCLEROSISD000690EFO:0000253AMYOTROPHIC LATERAL SCLEROSIS2
ASTHMAD001249EFO:0000270ASTHMA4
CARCINOMA, NON-SMALL-CELL LUNGD002289EFO:0003060NON-SMALL CELL LUNG CARCINOMA2
CEREBRAL HEMORRHAGED002543EFO:0005669INTRACEREBRAL HEMORRHAGE2
CHILD DEVELOPMENT DISORDERS, PERVASIVED002659EFO:0003756AUTISM SPECTRUM DISORDER2
CYSTIC FIBROSISD003550Orphanet:586CYSTIC FIBROSIS1
DIABETES MELLITUSD003920EFO:0000400DIABETES MELLITUS4
DIABETES MELLITUS, TYPE 1D003922EFO:0001359TYPE I DIABETES MELLITUS1
DIABETES MELLITUS, TYPE 2D003924EFO:0001360TYPE II DIABETES MELLITUS4
ENDOMETRIOSISD004715EFO:0001065ENDOMETRIOSIS2
FRIEDREICH ATAXIAD005621Orphanet:95FRIEDREICH ATAXIA3
HEPATITIS CD006526EFO:0003047HEPATITIS C INFECTION2
HEPATITIS, VIRAL, HUMAND006525EFO:0004196VIRAL HUMAN HEPATITIS INFECTION2
LEUKOPLAKIA, ORALD007972HP:0002745ORAL LEUKOPLAKIA2
LIVER DISEASESD008107EFO:0001421LIVER DISEASE3
METABOLIC SYNDROME XD024821EFO:0000195METABOLIC SYNDROME4
MILD COGNITIVE IMPAIRMENTD060825HP:0100543COGNITIVE IMPAIRMENT2
NON-ALCOHOLIC FATTY LIVER DISEASED065626EFO:0003095NON-ALCOHOLIC FATTY LIVER DISEASE2
OPIOID-RELATED DISORDERSD009293EFO:0005611OPIATE DEPENDENCE2
PANCREATIC NEOPLASMSD010190EFO:0002618PANCREATIC CARCINOMA2
PARKINSON DISEASED010300EFO:0002508PARKINSON'S DISEASE2
PERIPHERAL ARTERIAL DISEASED058729EFO:0004265PERIPHERAL ARTERIAL DISEASE0
RENAL INSUFFICIENCY, CHRONICD051436EFO:0003884CHRONIC KIDNEY DISEASE4
STROKED020521EFO:0000712STROKE2

Molecule Features

CHEMBL595 compound icon
Drug Type:Synthetic Small Molecule Rule of Five:Y First In Class:N Chirality:Racemic Mixture Prodrug:N Oral:Y Parenteral:N Topical:N Black Box:Y Availability Type:Prescription-only

Clinical Data

Number of clinical trials registered at clinicaltrials.gov
Number of reviews at The Cochrane Collaboration
Number of entries at British National Formulary

Structural Alerts

There are 2 structural alerts for CHEMBL595. To view alerts please click here.

Alternate Forms of Compound in ChEMBL


CHEMBL595

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Target Predictions

The two tables below display ChEMBL single-protein targets which are predicted to interact with CHEMBL595. A 1uM and 10 uM cut-off have been applied to ChEMBL bioactivity data used to generate the respective models and the yellow coloured rows correspond to genuine predictions, i.e. targets not included in the original training set for this compound.


1uM


ChEMBL_ID Target Name Organism Score
CHEMBL235 Peroxisome proliferator-activated receptor gamma Homo sapiens 1.000
CHEMBL4422 Free fatty acid receptor 1 Homo sapiens 1.000
CHEMBL2459 Peroxisome proliferator-activated receptor gamma Mus musculus 0.987
CHEMBL239 Peroxisome proliferator-activated receptor alpha Homo sapiens 0.787

10uM


ChEMBL_ID Target Name Organism Score
CHEMBL4422 Free fatty acid receptor 1 Homo sapiens 1.000
CHEMBL235 Peroxisome proliferator-activated receptor gamma Homo sapiens 1.000
CHEMBL2459 Peroxisome proliferator-activated receptor gamma Mus musculus 0.950
CHEMBL239 Peroxisome proliferator-activated receptor alpha Homo sapiens 0.945

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
356.4 356.1195 3.91 7 93.58 NEUTRAL


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
5 1 0 5 1 0


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
- 7.75 2.36 1.86 2 25 0.81

Compound Cross References

ATC A - ALIMENTARY TRACT AND METABOLISM
A10 - DRUGS USED IN DIABETES
A10B - BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BG - Thiazolidinediones
A10BG03 - pioglitazone

ChemSpider ChemSpider:HYAFETHFCAUJAY-UHFFFAOYSA-N
DailyMed pioglitazone hydrochloride
PubChem SID: 137275816 SID: 174007207 SID: 26756476
Wikipedia Pioglitazone

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL595



ACToR 105355-27-9 111025-46-8
Atlas pioglitazone
ChEBI 8228
DrugBank DB01132
eMolecules 902308
EPA CompTox Dashboard DTXSID3037129
Guide to Pharmacology 2694
Human Metabolome Database HMDB15264
KEGG Ligand C07675
LINCS LSM-1592
Mcule MCULE-2346786634
MolPort MolPort-028-603-922
Nikkaji J277.717G
PharmGKB PA450970
PubChem 4829
PubChem: Drugs of the Future 22395182
PubChem: Thomson Pharma 14828061
Selleck pioglitazone-actos
SureChEMBL SCHEMBL4121

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/HYAFETHFCAUJAY-UHFFFAOYSA-N spacer
spacer